ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Press release Key updates September 12, 2017
Leadership Page ProQR's leadership is a strong team with proven track record. Find out who is on our management team, supervisory board and scientific advisory board.
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update Press release Key updates February 28, 2018
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology Press release LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). January 08, 2018